A relative of a Covid-19 victim mourns at a crematorium in Jammu, India, on April 25. India’s Serum Institute, in collaborating with AstraZeneca, has complete access to all the necessary vaccine IP, yet has been unable to meet local and international needs. Photo: AP
A relative of a Covid-19 victim mourns at a crematorium in Jammu, India, on April 25. India’s Serum Institute, in collaborating with AstraZeneca, has complete access to all the necessary vaccine IP, yet has been unable to meet local and international needs. Photo: AP
David Dodwell
Opinion

Opinion

Outside In by David Dodwell

WTO battle over Covid-19 vaccine patents must not hold back world’s vaccination drive

  • Patents are not a critical barrier in the complex challenge of vaccine manufacture and roll-out, as seen in India
  • But arguing about patent waivers is distracting – people are dying in alarming numbers and our urgent priority must be to get shots into arms

A relative of a Covid-19 victim mourns at a crematorium in Jammu, India, on April 25. India’s Serum Institute, in collaborating with AstraZeneca, has complete access to all the necessary vaccine IP, yet has been unable to meet local and international needs. Photo: AP
A relative of a Covid-19 victim mourns at a crematorium in Jammu, India, on April 25. India’s Serum Institute, in collaborating with AstraZeneca, has complete access to all the necessary vaccine IP, yet has been unable to meet local and international needs. Photo: AP
READ FULL ARTICLE